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Abstract
Testing symptomatic individuals for a disease can deliver treatment resources, if tests’ results
turn positive, which speeds up their treatment and might also decrease individuals’ contacts
to other ones. An imperfect test, however, might incorrectly consider susceptible individuals
to be infected (false positives). In this case, testing reduces the epidemic in the expense of
potentially misclassifying individuals. We present a mathematical model that describes the
dynamics of an infectious disease and its testing. Susceptible individuals turn to “susceptible
but deemed infected” at rate θ. Infected individuals go to a state “infected and tested
positive” at rate α. Both rates are functions of test’s sensitivity and specificity. Analysis of
the model permits us to derive an expression for R0 and to find the conditions for reaching
R0 < 1, i.e., when the disease–free equilibrium is stable. We also present numerical results
to cover interesting scenarios such as using different tests and to compare these results.
We find for different sensitivity and specificity values the conditions permitting to get the
basic reproduction number R0 < 1, when originally, i.e., without testing, we would have
R0 > 1. We also find for a given sensitivity and specificity, the critical testing rate for
reaching R0 < 1.
1 Introduction
Treatment for communicable diseases can be quite costly. In the case of multiresistant tuber-
culosis infection the treatment per patient hast a cost that is much higher than an infection
from non-resistant strain of the pathogen (Cohen et al., 2009). This kind of treatment,
however, relies on testing diagnostics which have limitations. They basically might be more
accurate at the expense of time taken to have the results. It is often best to start treatment
as soon as the case is diagnosed, but the test results might suffer from the test imperfec-
tions. A model that indicates the cost of an epidemic as a function of the test sensitivity
and specificity can help mitigate or even avoid an epidemic.
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2The test imperfections appear from the probabilities of finding true positives or true
negatives. The first effect comes from the specificity, i.e., the probability that the test
indicates a negative diagnosis given that the tested individual does not have the pathogen.
If the specificity is not so high a significant fraction might be considered infected, whereas
those individuals are not. In some cases, starting treatment is the priority over waiting for
more accurate results. Therefore imperfections here might increase the cost.
Also, for real infected individuals, it is important that the test has good sensitivity, i.e.,
its rate of positive diagnosis in the case of positive tested individuals should be high. Again,
this comes at an expense of rapid diagnosis. The effect is that individuals that are correctly
diagnosed start treatment and reduce both the time they could infect other people and the
contacts to susceptible individuals, because of isolation and other measures.
In the case of tuberculosis (TB), for instance, an example is the Xpert (R) MTB/Rif
assay test for diagnosis of TB developed for the GeneXpert platform (WHO, 2011). It
consists of a molecular testing that can be done on demand and closer to individuals in
need. A meta-analysis of these reports was done by Walusimbi et al. (2013). The test
results take generally about three hours, whereas a more established protocol (sequence of
tests and surveys) would result in treatment starting only after a few days. Walusimbi et al.
(2013) found pooled specificity and sensitivity estimated at 0.67 (CI: 0.62 – 0.71) and 0.98
(CI: 0.97–0.99), respectively.
In the case of hepatitis C, de Paula Scalioni et al. (2014) report results for rapid tests
which can have high values for both specificity and sensitivity, but can vary depending on
the kind of sample (serum, whole blood, saliva).
Eaton and Hallett (2014) estimate the effect of early–stage transmission of HIV, i.e.,
before testing individuals for HIV infection, a stage at which they did not started receiving
treatment.
The recent literature on disease modeling and diagnosis is extensive. We point to the
review by Zwerling et al. (2015) on modeling of TB, investigating diagnosis and therapies.
In particular, Raimundo et al. (2014) have a an approach on modeling focused on resistant
TB. Salje et al. (2014) discuss the implementation of testing for multiresistant TB in India.
Also, Cox (2014) in a recent editorial described the need for simple models for the sake of
interpretation of results, especially for people from outside of modeling. In our model, we
consider the minimum number of variables to give important insights.
In this paper we present a modeling approach that permits us to obtain R0 as a function
of testing specificity and testing sensitivity. Our model is described as a set of ordinary
differential equations, close to a SIR model. We present analytical results from the model
and also some numerical simulations that show the cost increase due to testing along with
the desired effect of the mitigiation or avoidance of epidemics.
2 Model
Our ODE model, leveraged from a classical SIR model, has two components: Sm, to describe
the number of susceptible individuals that take the test and are deemed incorrectly to be
3infected, and Im, that describes the number of infected individuals that are test–diagnosed
positive and start treatment. As usual, we describe the other compartments: S, to describe
number of suscetibles, I for number of infected individuals and R for recovered ones.
Individuals that are susceptible get infected at rate β. These individuals are called the
regular susceptibles. The model describes the situation in which susceptible individuals take
a test and are deemed incorrectly to be infected at rate βm. This class is for the “susceptible
but deemed infected”. We generally assume that β > βm, for infected ones might be under
treatment, possibly in isolation, therefore these individuals are less likely to transmit the
pathogen to another individual.
Individuals leave the population at rate µ, equal for all classes, because we assume a
disease that does not cause significantly higher mortality rate. The rate of new individuals
entering the population (e.g., typically by birth) is also given by µ to result in a constant
population size. We normalize all variables by the population size.
Individuals pass from susceptible to a susceptible–deeemed–infected state at rate θ. This
will depend on the rate r at which individuals are tested and the test specificity . The test
specificity is given by the probability of true negatives, i.e. P(test- | uninfected) (Newman,
2003). Hence, θ is the product of the rate r and P(test+ | uninfected)=1 − , such that
θ = r(1− ).
The test sensitivity ψ is given by the rate of true positives, i.e. P(test+ | infected)
(Newman, 2003). Also, infected individuals can be tested and, if the test is positive, start
treatment. Therefore, infected individuals will pass from class I of regular infected indi-
viduals to the class of Im infected under treatment at rate α = rψ. Finally, we assume
that individuals that are under treatment get to recover faster. Therefore, regular infected
individuals recover at a rate γ, whereas infected–under–treatment individuals recover at rate
γm. Typically, γm > γ.
We present the ODE system that describes this model:
dS
dt
= −θS − βS(I + Im)− µS + µ
dSm
dt
= θS − βmSm(I + Im)− µSm
dI
dt
= βS(I + Im) + βmSm(I + Im)− (α+ γ + µ)I (1)
dIm
dt
= αI − γmIm − µIm
dR
dt
= γmIm + γI − µR
Table 1 contains a summary of the variables and parameters, and their respective de-
scriptions as well as values used in this work for investigation of numerical scenarios.
Cost of infection
We apply here a model in which treatment cost varies linearly with the number I of infected
persons and the number Im, but also the number Sm of susceptible but deemed infected.
4Table 1. Model parameters, variables and respective descriptions.
Parameters Description Value
β transmission rate in state S .15
γ recovery rate in state I .1
γm recovery rate in state Im .15
βm transmission rate in state Sm .1
µ mortality/birth rate 0.003
r testing rate different values
ψ test sensitivity different values
 test specificity different values
α = rψ rate at which individuals enter state Im different values
θ = r(1− ) rate for entering state Sm different values
Variable
S number of susceptible individuals normalized
Sm number of susceptible individuals but deemed infected normalized
I number of infected individuals normalized
Im number of tested–positive infected individuals normalized
R number of recovered individuals normalized
The cost is a function of the rate r and time τ , given by Ca(r) =
∫ τ
0 wSSm(r, t)+wII(r, t)+
wMIm(r, t)dt. The relative cost C(τ) is given by the ratio between the cost under rate r
and the cost at no treatment, i.e., r = 0, as follows:
C(τ) =
∫ τ
0 wSSm(r, t) + wII(r, t) + wMIm(r, t)dt∫ τ
0 wSSm(0, t) + wII(0, t) + wMIm(0, t)dt
, (2)
where wS , wI , and wM are weights to each of the variables Sm, I, and Im, respectively.
3 Results
System dynamics
We start the analysis by considering that there are only susceptible individuals, without any
infectious individuals. In this case, we have clearly I(t) = 0, Im(t) = 0 and the left hand
side of equations in 1 become zero. The solution is given by
(Sf , Sm,f , If , Im,f , Rf ) = (
µ
µ+ θ
,
θ
µ+ θ
, 0, 0, 0).
As noted above, he system has an equilibrium in which Sm = θµ+θ . Therefore, a fraction
of the population demands treatment resources even when there are no infected individuals.
5We follow from this initial result to derive a matrix that describes the “flows” into in-
fectious states and out from infectious states. Note that the state Sm is not really an
infectious state, since the individual is still susceptible. We apply the method of analyzing
the Next-Generation Matrix (NGM, described by Diekmann et al. (2009)) K and find:
K =
 βµµ+θ+βmθµ+θα+γ+µ + α
(
βµ
µ+θ
+βmθ
µ+θ
)
(α+γ+µ)(γm+µ)
βµ
µ+θ
+βmθ
µ+θ
γm+µ
0 0
 .
The dominant eigenvalue of the matrix K given by the spectral radius of matrix K
results in the basic reproduction number R0, the number of individuals that get infected
upon a single infected individual:
R0 =
βµ+ βmθ
(θ + µ)(γ + µ+ α)
(1 +
α
γm + µ
). (3)
Endemic state
Analysis of the system dynamics permits us to show that it reaches equilibrium in en endemic
state, as expected depending on the threshold given by R0. The endemic state is given by:
S∗ =
µ
θ + µ+ βI∗(1 + α/(γm + µ))
S∗m =
(
θ
βmI∗(1 + α/(γm + µ)) + µ
)(
µ
θ + µ+ βI∗(1 + α/(γm + µ))
)
I∗m =
αI∗
γm + µ
R∗ =
γm
α
γm+µ
+ γ
µ
I∗
Using the equations above we can find an equation containing only the number I∗ of
infected in the endemic state. Solving the equation for I∗ requires finding the solutions to
the polynomial
pI(I) =
(θ + µ)µ
ββm(1 + α/(γm + µ))2
(R0 − 1) + I
(
µ
γ + α+ µ
− (θ + µ+ βµ/βm)
β(1 + α/(γm + µ))
)
− I2 (4)
Clearly, R0 > 1 is a sufficient condition for a biologically feasible solution (a nonnegative
real root). In this case,
I∗ =
√
b2 + 4u(R0 − 1)
2
− b
2
(5)
where b = µγ+α+µ − (θ+µ+βµ/βm)β(1+α/(γm+µ)) and u =
(θ+µ)µ
ββm(1+α/(γm+µ))2
.
6Conditions involving the testing rate
The rates θ and α at which individuals are, respectively, deemed infected but still susceptible
and diagnosed infected both depend on a treatment rate r. These rates will then depend on
the testing rate and the test specificity and sensitivity. By applying the rates α = rψ and
θ = r(1− ) depending on the rate r, and the specificity  and sensitivity ψ, we rewrite R0:
R0 =
(βmr(1− ) + βµ)(rψ + γm + µ)
(r(1− ) + µ)(rψ + γ + µ)(γm + µ) .
It is interesting to note that if r → ∞, R0 → βm(1−)ψ(γm+mu)ψ(1−) =
βm
γm+µ
. This expression
is the equal to the R0 obtained for a SIR system at an infection rate βm and recovery rate
γm. When r = 0, we have a regular SIR model formulated with parameters β, γ and µ,
such that R0 = βγ+µ . Therefore, these are the two extreme values for R0 when varying the
testing rate r.
Conditions for R0 < 1
We consider now conditions for the disease not to go to the endemic state, i.e., for which
R0 < 1. This condition would require that a polinomial p(r) < 0, where
p(r) = (1− )ψ(βm − γm − µ)r2 +
(1− )(γm + µ)(βm − γ − µ) + µψ(β − γm − µ)r +
µ(γm + µ)(β − γ − µ).
The typical situation for analyzing p(r) < 0 is that an epidemic occurs if no treatment
is realized, i.e. in this case R0 > 1, when r = 0. Therefore, we would expect the normal
SIR threshold condition β > γ + µ. Let us first assume that βm < γm + µ, which is the
condition for the polynomial to be concave down. As shown when r → ∞, this condition
permits an R0 < 1, which suggests that under treatment it is possible to bring the system
to R0 = 1 for a finite r. Indeed, p(r) has two real roots, a positive root rc and a negative
one. Therefore we would need r > rc in order to have p(r) < 0, and consequently R0 < 1.
If we consider instead an asymptotic condition βm/(γm + µ) > 1, given the reasonable
assumptions γm > γ and β > βm, would guarantee β > γ + µ, and, by consequence,
β > βm > γm + µ > γ + µ
In this case, either there are no purely real roots or none of the roots are positive. Hence,
p(r) > 0, R0 > 1. This essentially means that increasing the testing rate permits to decrease
R0, but not to avoid an epidemic.
Different scenarios: numerical simulations
Here we consider the model as given by Table 1. Values for parameters β, βm, γ, γm, µ
were chosen such that we have R0 on a domain that permits situations from epidemic to
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Figure 1. Countour plot under different testing rates. We show here testing rates
from top to bottom: r = 0.02, r = 0.04, r = 0.06, r = 0.08. The intensity of the color
indicates the R0: colors closest to white are the smallest R0 values, whereas colors close to
red indicate high values for R0.
controlled disease. We should note that under no treatment, we have an R0 condition: R0 =
β
γ+µ = 1.456. When we have the limiting condition, r → ∞, we find R0 = βmγm+µ = 0.654.
Therefore these two values are the extreme points that we can find by considering different
scenarios for θ and α (or alternatively different values for r, , and ψ).
We first consider varying the sensitivity and specificity for different testing rates given
by r. Figure 1 shows us from top to bottom the different countour plots for values of the
basic reproduction number R0 when varying the testing rate r from r = 0.02 to r = 0.08.
The intensity of the color permits us to observe the R0 values, in which a lighter-intensity
color depicts smaller values for R0. As expected if we increase the testing rate r, the plots
become lighter, meaning that epidemics are less likely under higher testing rates.
We also consider the cost ratio given by Eq. 2 and varying the testing rate r. Here,
we consider the sensitivity equal to 0.98 and the specificity at 0.67, values found for a TB
test by pooled results (Walusimbi et al., 2013), even though the model might be simple for
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Figure 2. Cost ratio. Each of the curves depict the cost ratio obtained over time for
different testing rates r. Curves vary from r = 0 (dark blue) to r = 10 (light blue).
analyzing complex scenarios that TB presents. Figure 2 shows multiple curves, in which
we observe for higher testing rates (lighter colors) the cost ratio increasing to higher peaks.
This is expected because more individuals are under treatment.
Finally, we show for the same testing rates as in Figure 2, how the epidemic develops
(or not). We observe in Figure 3 that the incidence effectively decreases as the testing rate
increases (lighter colors), which is the opposite effect of the cost ratio. Therefore, the ideal
point should be a testing rate r that enables a basic reproduction number R0 < 1, but
probably close to the threshold such that the cost ratio is not prohibitive.
4 Discussion
In this paper we establish a mathematical modeling that permits us to analyze the effects
of imperfect testing on the dynamics of diseases. The modeling considers specificity and
sensitivity of the testing. Therefore, given these two parameters we can find R0, which tells
us if the disease–free state is stable. In this case, even if few disease cases appear, we would
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Figure 3. Incidence at different testing rates. Each of the curves show the number
of infected persons under different testing rates varying from r = 0 (dark blue) to r = 10
(light blue). The number of infected persons are found by summing variables I and Im.
not expect an epidemic to occur. Alternatively, we can find a testing rate that can bring
the disease to a controled level for a specific test, for which specificity and sensitivity has
been estimated.
The testing rate, however, also raises the total treatment costs given a time interval.
Hence, as expected, it is not viable to raise the testing rate indefinitely, for cost–effectiveness,
especially when the per–capita treatment is already costly.
We believe our model is particularly helpful to give insights about regions (controlled
disease/epidemic, cost prohibitive/viable costs). We expect to extend the work to other
similar models, in particular a SEIR model. This would be the case for diseases such as
tuberculosis, and especially multi–resistant tuberculosis, which requires expensive treatment.
We considered estimated rates for sensitivity and specificity typical of tests, such as a
tuberculosis test GenExpert (Walusimbi et al., 2013), to evaluate possible scenarios. We
also intend to study data from public health systems that show the impact of introducing
treatment and the cost associated with the treatment.
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The imperfect testing might bring individuals to states, for instance a false–positive
infected, in which they might be diagnosed after a slow test and should return to susceptible
state. We intend to treat this case in future work.
We consider the expected cases in which β > βm, a smaller force of infection under
treatment, and γm > γ, a speedy recover rate under treatment. Those are reasonable
assumptions in most cases. Different cases, however, can be considered for more complex
scenarios. In the case of sexual–contact diseases, maybe some individuals might incur on
reckless behavior, which would instead not increase the treatment, but increase the force
of infection, as discussed by Wilson et al. (2008). We intend to pursue investigating such
“anomalies” in the framework of our model.
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